
Late-breaking ESMO 2026 data show PFS gains with 3 antibody-drug conjugates, a 6-year OS benefit with adjuvant ribociclib, and no OS gain with pembrolizumab.
Katharine Yao, MD, gives an overview of an analysis that looked at patient preferences prior to surgery.
Katharine Yao, MD, director, breast surgical program, NorthShore University HealthSystem, Evanston, Illinois, clinical associate professor, surgery, Pritzker School of Medicine, University of Chicago, gives an overview of an analysis that looked at patient preferences prior to surgery.
<<<






